DOCSLIB.ORG

The TERMIS-Americas 2013 Annual Conference & Exposition PROGRAM

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
The TERMIS-Americas 2013 Annual Conference & Exposition PROGRAM P ROGRAM The TERMIS-Americas 2013 Annual Conference & Exposition 3 CELEBRATING 25 YEARS g/am201 OF TRANSFORMATIVE r SCIENCE & ENGINEERING .termis.o w November 10-13, 2013 ww Hyatt Regency Atlanta Atlanta, Georgia Hosted by: TABLE of CONTENTS Welcome …. 4 General Information …. 5 Bench to Business Workshop …. 6 Women in TERM Luncheon …. 7 Opening Symposium …. 8 Opening Day Schedule Sunday, November 10 …. 9 Podium Presentations Monday, November 11 …. 10 - 14 Podium Presentations Tuesday, November 12 …. 15 - 18 Podium Presentations Wednesday, November 13 …. 19 - 24 Poster Session I Monday, November 11 …. 25 - 32 Poster Session II Tuesday, November 12 …. 33 - 41 Student & Young Investigator Section Welcome & Activities …. 43 - 44 Student Poster Competition …. 45 WFIRM YIA Award Winners …. 46 TERMIS-AM 2013 Award Winners …. 47 - 48 Exhibitor Floorplan and Listing …. 49 - 52 Sponsors …. 53 - 54 OPENING RECEPTION Hosted by the Exhibitors and Sponsors Sunday, November 10, 2013 7:00 - 9:00 PM Located in the Regency Ballroom 3 GENERAL INFORMATION November 10, 2013 SCIENTIFIC ADVISORY COMMITTEE Robert Guldberg, PhD, Georgia Institute of Technology, Dear Fellow TERMIS Attendees: Conference Chair and TERMIS-AM Chapter Chair On behalf of the scientific advisory committee, the international community of TERMIS members, and everyone involved in supporting the TERMIS-Americas (TERMIS-AM) 2013 Conference, we would like Todd McDevitt, PhD, Georgia Institute of Technology, to personally welcome you to Atlanta, Georgia. Scientific Program Chair The theme of this year’s meeting, “Celebrating 25 years of Transformative Science & Engineering,” Stephen Badylak, PhD, MD, University of Pittsburgh was inspired by the first federally funded tissue engineering workshop in 1998. The opening plenary symposium on Sunday will provide talks from several leaders on how key areas of the field have Dolores Baksh, PhD, Organogenesis evolved over the past 25 years, as well as share insights on future directions of the field. Mário Barbosa, PhD, INEB Jason Burdick, PhD, University of Pennsylvania Planning for the 2013 TERMIS-AM Conference has been a great success, reflected by an anticipated Robert Christy, PhD, United States Army Institute of Surgical Research record-breaking attendance of over 1,000. We received over 600 abstracts, resulting in approximately 200 oral presentations and 400 poster presentations - a clear testament to the continued growth of this Jennifer Elisseeff, PhD, Johns Hopkins University community. As a result, we have added several new and exciting elements to the program, including John Fisher, PhD, University of Maryland the first ever TERMIS-AM conference dinner, a Women in Tissue Engineering & Regenerative Medicine Andrés García, PhD, Georgia Institute of Technology luncheon, and a session focused on public policy. These new activities as well as enhancement of existing outreach and training opportunities will be supported in part by grants from the National Sharon Gerecht, PhD, Johns Hopkins University Institutes of Health and National Science Foundation. Sarah Heilshorn, PhD, Stanford University We are very excited about this year’s scientific program comprised of session topics that focus on Dietmar Hutmacher, PhD, Queensland University of Technology the fundamental principles, emerging strategies, and practical applications of the latest advances in Gilson Khang, PhD, Chonbuk National University tissue engineering and regenerative medicine. In addition to emphasizing basic and applied scientific Masahiro Kino-Oka, PhD, Osaka University research themes that broadly impact different tissue and organ systems, we have also included a series of sessions dedicated to clinical translational work. Alison McGuigan, PhD, University of Toronto Welcome Antonios Mikos, PhD, Rice University We will hear from distinguished keynote lecturers speaking about innovative approaches that William Murphy, PhD, University of Wisconsin impact new tissue engineering and regenerative medicine strategies, including Deepak Srivastava, MD, Younger Director of the Gladstone Institute of Cardiovascular Disease and Director of Sean Palecek, PhD, University of Wisconsin the Roddenberry Stem Cell Center at Gladstone; Valerie M. Weaver, PhD, Associate Professor, Abhay Pandit, PhD, National University of Ireland Departments of Surgery and Bioengineering and Therapeutics, and Director, Center for Bioengineering and Tissue Regeneration, University of California, San Francisco; and James M. Wells, PhD, Endowed Shelly Sakiyama-Elbert, PhD, Washington University Chair in Regenerative Medicine and Perinatal Endocrinology and Director, Pluripotent Stem Cell Katja Schenke-Layland, PhD, Fraunhofer Institute for Facility, Cincinnati Children’s Hospital Medical Center. Interfacial Engineering and Biotechnology IGB Realizing the importance of a strong trainee network, the Student and Young Investigator Section of Michael Sefton, ScD, University of Toronto the Americas chapter (SYIS-AM) has organized a number of exciting activities at the meeting. With Johnna Temenoff, PhD, Georgia Institute of Technology support from the National Science Foundation, we were able to expand many of the SYIS events this year, including doubling the numbers of participants of the Mentoring Lunch and Career Panel. In Ned Waller, PhD, MD, Emory University addition, they have organized the first-ever local area high school outreach event. Jennifer West, PhD, Duke University Finally, conference guests are invited to an evening of fun and celebration at the conference gala dinner and reception to be held Tuesday evening at the World of Coca-Cola, hosted by Georgia Institure of Technology Parker H. Petit Institute for Bioengineering and Bioscience. ONSITE REGISTRATION AND CONFERENCE CHECK-IN We are very proud to host the TERMIS-AM 2013 meeting and welcome you to our city. Although it Photo ID is required at check-in. has been over a year in the making, the success of this year’s meeting reflects the efforts of past chairs, The registration desk will be open at the following times: advisory committees, trainees and attendees, to build a healthy and vibrant society and for that reason, • Sunday, November 10 from 7:00 AM – 7:00 PM we encourage you to celebrate this week with us and enjoy the 25th anniversary of our field’s birth! • Monday, November 11 from 7:00 AM – 5:00 PM Sincerely, • Tuesday, November 12 from 7:00 AM – 5:00 PM • Wednesday, November 13 from 7:00 AM – 5:00 PM Robert E. Guldberg, PhD Todd C. McDevitt, PhD TERMIS-AM 2013 Conference Chair TERMIS-AM 2013 Scientific Program Chair OPENING RECEPTION Executive Director of the Parker H. Petit Institute Petit Faculty Fellow, Parker H. Petit Institute for • Sunday, November 10, 2013 for Bioengineering and Bioscience, Bioengineering and Bioscience Professor, George W. Woodruff School of Director, Stem Cell Engineering Center, Georgia • 7:00 PM - 9:00 PM Mechanical Engineering Institute of Technology • Exhibit Hall – Regency Ballroom Georgia Institute of Technology Associate Professor, Wallace H. Coulter Department 4 of Biomedical Engineering 5 Georgia Institute of Technology and Emory University PRECONFERENCE WORKSHOP • SUNDAY, NOVEMBER 10, 2013 • 8:00AM – 2:00PM WOMEN IN TISSUE ENGINEERING AND REGENERATIVE MEDICINE LUNCHEON Bench to Business Workshop “Avoiding Traps” Organized by the TERMIS-AM Industry Committee Sunday, November 10th from 11:30 AM - 2:00 PM This workshop will feature experienced speakers working directly on the challenges associated with Registration for the event is FREE. The maximum number of attendees for the technology transfer for the commercialization of academic research. Topics will include designing Women in TERM Luncheon is 100, so registrations will be awarded on product development studies to facilitate industrial interest, translation and commercialization, a first-come first-serve basis. developing and protecting commercially-relevant intellectual property, working with university technology transfer offices, partnering with existing companies including biotechnology and Invited Discussants: establish corporate entities, developing a business plan and attracting funding to support Gordana Vunjak-Novakovic, Columbia University commercialization of the academic technology. Attendees will benefit from real-world case studies, Molly Shoichet, University of Toronto practical examples and guidance from experienced thought leaders. The goal of the workshop is Bob Nerem, Georgia Institute of Technology for attendees to leave with actionable concepts of how to evaluate their current research enterprise Michael Sefto, University of Toronto for technology and start the process toward potential commercialization. The knowledge and tools Milica Radisic, University of Toronto gained from the workshop is anticipated to represent successful approaches used to accelerate the Shelley Sakayama-Elbert, Washington University commercialization of your research efforts. Alison McGuigan, University of Toronto Katja Schenke-Layland, University Women’s Hospital Tübingen Registration fee: $99.00 Research efforts in tissue engineering have intensified in the past 25 years, coinciding with the increased efforts to promote enrollment of female students in all areas of engineering. Agenda: As tissue and biomedical engineers, we have been successful in recruiting female students into our undergraduate and graduate programs. More than 50% of PhD degrees are 8:00 AM to 8:15 AM Opening Remarks awarded each year to female students in areas of Engineering
Load more

Recommended publications
  • Bolderboulder 2005 - Bolderboulder 10K - Results Onlineraceresults.Com
    BolderBOULDER 2005 - BolderBOULDER 10K - results OnlineRaceResults.com NAME DIV TIME ---------------------- ------- ----------- Michael Aish M28 30:29 Jesus Solis M21 30:45 Nelson Laux M26 30:58 Kristian Agnew M32 31:10 Art Seimers M32 31:51 Joshua Glaab M22 31:56 Paul DiGrappa M24 32:14 Aaron Carrizales M27 32:23 Greg Augspurger M27 32:26 Colby Wissel M20 32:36 Luke Garringer M22 32:39 John McGuire M18 32:42 Kris Gemmell M27 32:44 Jason Robbie M28 32:47 Jordan Jones M23 32:51 Carl David Kinney M23 32:51 Scott Goff M28 32:55 Adam Bergquist M26 32:59 trent r morrell M35 33:02 Peter Vail M30 33:06 JOHN HONERKAMP M29 33:10 Bucky Schafer M23 33:12 Jason Hill M26 33:15 Avi Bershof Kramer M23 33:17 Seth James DeMoor M19 33:20 Tate Behning M23 33:22 Brandon Jessop M26 33:23 Gregory Winter M26 33:25 Chester G Kurtz M30 33:27 Aaron Clark M18 33:28 Kevin Gallagher M25 33:30 Dan Ferguson M23 33:34 James Johnson M36 33:38 Drew Tonniges M21 33:41 Peter Remien M25 33:45 Lance Denning M43 33:48 Matt Hill M24 33:51 Jason Holt M18 33:54 David Liebowitz M28 33:57 John Peeters M26 34:01 Humberto Zelaya M30 34:05 Craig A. Greenslit M35 34:08 Galen Burrell M25 34:09 Darren De Reuck M40 34:11 Grant Scott M22 34:12 Mike Callor M26 34:14 Ryan Price M27 34:15 Cameron Widoff M35 34:16 John Tribbia M23 34:18 Rob Gilbert M39 34:19 Matthew Douglas Kascak M24 34:21 J.D.
    [Show full text]
  • Jacob Markowitz Award Given to Past President
    Biomaterials Forum, the official news magazine of the Society For Biomaterials, is published quarterly to serve the biomaterials community. Society members receive Biomaterials Forum as a benefit of membership. Non-members may subscribe to the magazine at the annual rate of $48. For subscription information, or membership inquiries, contact the Membership Department at the Society office (e-mail: [email protected]) or visit the Society’s Web site, www.biomaterials.org. The official news magazine of the SOCIETY FOR BIOMATERIALS • Volume 26, Issue 4 It is the policy of the Society For Biomaterials that all articles reflect only the views of the Executive Editor Martine LaBerge, Clemson University authors and that publication of articles or 501 Rhodes Research Center, Clemson, SC 29634-0905 Phone: (864) 656-5557 • Fax: (864) 656-4466 advertisements within Biomaterials Forum does E-mail: [email protected] not constitute endorsement by the Society or its agents of products, services, or views expressed Managing Editor Frank Scussa, Society For Biomaterials 17000 Commerce Parkway, Mt. Laurel, NJ 08054 herein. No representation is made as to the Phone: (856) 439-0500 • Fax: (856) 439-0525 accuracy hereof and the publication is printed E-mail: [email protected] subject to errors and omissions. Articles that do Government News John A. Tesk, National Institute of Standards and Technology not have an author byline may originate from Contributing Editor Industrial Liaison Office press releases. The Society For Biomaterials 100 Bureau Dr., Stop 1005, Gaithersburg, MD 20899-1005 Phone: (301) 975-6799 • Fax: (301) 963-9143 retains press releases on file for a period of one E-mail: [email protected] year from the date of publication.
    [Show full text]
  • Pluripotent Stem Cells: the Search for the "Perfect" Source
    Minnesota Journal of Law, Science & Technology Volume 12 Issue 2 Article 10 2011 Pluripotent Stem Cells: The Search for the "Perfect" Source Nancy M.P. King Christine Nero Coughlin Anthony Atala Follow this and additional works at: https://scholarship.law.umn.edu/mjlst Recommended Citation Nancy M. King, Christine N. Coughlin & Anthony Atala, Pluripotent Stem Cells: The Search for the "Perfect" Source, 12 MINN. J.L. SCI. & TECH. 715 (2011). Available at: https://scholarship.law.umn.edu/mjlst/vol12/iss2/10 The Minnesota Journal of Law, Science & Technology is published by the University of Minnesota Libraries Publishing. King NMP, Coughlin CN, Atala A. Pluripotent Stem Cells: The Search for the “Perfect” Source. Minnesota Journal of Law, Science & Technology. 2011;12(2):715-30. Pluripotent Stem Cells: The Search for the “Perfect” Source Nancy M.P. King*, Christine Nero Coughlin** & Anthony Atala*** Anyone who dreamed that the public controversy over human embryonic stem cell (hESC) research had begun to die down was rudely awakened by the decision in Sherley v. Sebelius.1 On August 23, District of Columbia District Court Judge Royce Lamberth issued a preliminary injunction halting federal funding of research using newly created hESC lines until the plaintiffs’ challenge to the 2009 liberalization of funding guidelines can be heard.2 On September 9, 2010, the Court of Appeals for the District of Columbia temporarily stayed Judge Lamberth’s order,3 and on September 28, 2010, the Court of Appeals ordered that the appeal be expedited and granted the Obama administration’s motion to permit federally © 2011 Nancy M.P.
    [Show full text]
  • Scientists Prove Bioengineered Uteri Support Pregnancy 29 June 2020
    Scientists prove bioengineered uteri support pregnancy 29 June 2020 regenerative medicine and a number of the basic principles of tissue engineering and regenerative medicine were first developed at the institute. Their strategy to bioengineer functional tissues using a patient's own cells seeded onto biodegradable scaffolds has been effectively explored in preclinical studies and applied successfully in human patients to restore function in tubular and in hollow non-tubular organs. Regenerative medicine and tissue engineering technologies have emerged as an attractive option for overcoming donor organ A CT image of a bioengineered rabbit uterus with a shortages and other limitations of transplantation fetus, proving the organ supported fertilization, fetal from donors. The scientists used the same development. Credit: Wake Forest Institute for bioengineering strategy to engineer the uterus, a Regenerative Medicine (WFIRM) more complex organ with higher functional requirements involving support of embryo implantation and fetal development. In new research from the Wake Forest Institute for For this study, rabbits were randomly assigned to Regenerative Medicine (WFIRM), scientists have four groups: (1) a tissue-engineered uteri group that shown that bioengineered uteri supported received a cell-seeded scaffold using the animals' fertilization, fetal development, and live birth with own cells; (2) a non-seeded scaffold group, that normal offspring. With further development, this received a polymer scaffold only; (3) a subtotal approach may someday provide a regenerative uterine excision-only control group, where the medicine solution for women with the inability to subtotal excision was repaired by suturing and (4) a get pregnant due to uterine dysfunctional infertility normal control group, where animals underwent a sham laparotomy.
    [Show full text]
  • Uehling Lectures
    2009 U Nonprofit Organization US Postage PAID Madison, Wisconsin EHLING Permit No. 658 OCPD in Medicine and Public Health 2701 International Lane, #208 Madison, WI 53704-3126 alem, NC alem, S Winston- chool of Medicine of chool S niversity U Foreset Wake and Public Health Health Public and Continuing Professional Development in Medicine Medicine in Development Professional Continuing egenerative Medicine egenerative R for Institute Director, Public Health, Department of Urology, and Office of of Office and Urology, of Department Health, Public rology rology U of Department Chairman, & Professor chool of Medicine and and Medicine of chool S Wisconsin of niversity U Anthony Atala, MD Atala, Anthony : Y B D RE O S SPON tephen Y. Nakada, MD Nakada, Y. tephen S R: O T C RE I D URSE O C , W , M ISCONSIN ADISON E E CATION U D TIVE U XEC C F OR F ENTER NO U L 6, 2009 6, N , F L U 2009 OVEMBER RIDAY RER U ECT EHLING L ECT 2009 UEHLING LECT U RES State of the Art Regenerative Dr. David T. Uehling was born and raised outside Chicago, and completed his urology training at Northwestern. Following a Medicine successful stint as a fellow at Chicago Children's Memorial Hospital, he joined the and staff at the University of Wisconsin in 1965. Clinically, Dr. Uehling developed a statewide Update in Pediatric Urology practice in pediatric urology, and has served the children of Wisconsin admirably for 40 U years. NOVEMBER 6, 2009 Throughout his career, Dr. Uehling distinguished himself in research, with FL U NO CENTER FOR EXEC U TIVE ED U CATION REScontinuous NIH funding in the treatment of urinary tract infections.
    [Show full text]
  • Anthony Atala, M.D
    Regenerative Cell Therapies: Making Safe and Effective Treatments Available to Patients Anthony Atala, M.D. Anthony Atala, MD, is the G. Link Professor and Director of the Wake Forest Institute for Regenerative Medicine, and the W. Boyce Professor and Chair of Urology. Dr. Atala is a practicing surgeon and a researcher in the area of regenerative medicine. Dr. Atala is Editor-in-Chief of three journals, including Stem Cells Translational Medicine, and Bioprinting. Dr. Atala was elected to the Institute of Medicine of the National Academies of Sciences, to the National Academy of Inventors as a Charter Fellow, and to the American Institute for Medical and Biological Engineering. Dr. Atala is a recipient of the US Congress funded Christopher Columbus Foundation Award, bestowed on a living American who is currently working on a discovery that will significantly affect society; the World Technology Award in Health and Medicine, for achieving significant and lasting progress; the Edison Science/Medical Award for innovation; the Smithsonian Ingenuity Award; the R&D Innovator of the Year Award, and the Fast Company World Changing Ideas Award for Bioprinting Tissue and Organs. Dr. Atala’s work was listed twice as Time Magazine’s top 5 medical breakthroughs of the year, and once as one of 5 discoveries that will change the future of organ transplants. He was named by Scientific American as one of the world’s most influential people in biotechnology, by U.S. News & World Report as one of 14 Pioneers of Medical Progress in the 21st Century, by Life Sciences Intellectual Property Review as one of the top key influencers in the life sciences intellectual property arena, and by Nature Biotechnology as one of the top 10 translational researchers in the world.
    [Show full text]
  • Fall '06 Vol. I, Issue IV
    InterLink: Fall 2006 Volume I, Issue IV Letter from the Editor In This Issue … Dear Colleagues and Friends, Letter from the Editor Continental Council Updates from Chairs: I hope that you had a peaceful und relaxing holiday season AP: Hai Bang Lee, PhD 2-3 and started the New Year with full vigor and energy. EU: Ivan Martin, PhD 4 NA: Anthony Atala, MD 5-7 As we all know, tissue engineering corresponds to the confluence of a multifaceted display of pre-existing disciplines Features on Tissue Engineering Laboratories: from three quite different domains: namely clinical medicine, AP: Kyoto University 7-14 engineering, and science. The ultimate goal for tissue EU: Imperial College London 14-19 engineers should be to move their research into the clinical NA: University of California-San Diego 19-26 domain, and are best understood as specific examples of general problem-solving strategies employed by surgeons and SYIS: Student & Young Investigator Section 27 physicians. For example, orthopedic surgeons have been investigating many different kinds of implants that may promote Sponsors 27 bone regeneration. From a clinical perspective, what matters is not so much as whether the active agent in a scaffold or Upcoming TERMIS Meetings 28 matrix consists of stem cells, bone morphogenetic proteins, or gene therapy vectors, but whether it is therapeutically effective. Membership Definition/Benefits 29 Similarly, nephrologists may view the dialysis machine, as a tissue engineered "artificial kidney" or a functional, Online Access to Tissue Engineering 30 biocompatible micro renal support device created via nuclear Online Journal Package 30 transplantation as possibilities along a seamless spectrum of therapeutic options rather than in terms of the radically Encourage Institutional Subscriptions 30 different underlying definitions or technologies they represent.
    [Show full text]
  • Top 50 Most Influential People on Stem Cells Today Terrapinn.Com/ TOP 50 Stem Cell Influencers Terrapinn.Com/Loyaltyasia
    Top 50 most influential people on Stem Cells today terrapinn.com/ TOP 50 stem cell influencers terrapinn.com/loyaltyasia Who are the most influential people in stemcell the global stem cell and cell therapy field? This is the question we asked our blog subscribers, LinkedIn group members and anyone in our contact network to compile a comprehensive list of the Top 50 as named by you. The following 50 personalities were picked based on their career achievements whether this was groundbreaking discovery and research or innovation, funding, lifetime dedication or simply because they might have inspired others to do well. It is great to see that we have representatives from all aspects including industry, governments, philanthropy, academia and even showbiz. Thank you to everyone who has helped us compile the list and please feel free to share it with your colleagues. blogs.terrapinn.com/ TOP 50 stem cell influencers 50 49 48 terrapinn.com/loyaltyasia totalbiopharma No. 50 Paul Knoepfler Dr Catherine Prescott Michael Werner Associate Professor Owner Partner UC Davis School of Medicine Biolatris Holland and Knight Cathy brings over 20 years of experience in [email protected] Werner has more than 25 years of Dr Paul Knoepfler is an Associate Professor in research, management and business within healthcare law, lobbying, policy Cell Biology and Human Anatomy at the UC the life-science and venture capital sectors. development and regulatory experience in Davis School of Medicine, where his lab studies She is the Founder Director of Biolatris Ltd., Washington. In addition to forming the stem cells and cancer. He is also a faculty Co-founder and Director of UniverCELL Market Alliance for Regenerative Medicine and member of the UC Davis Genome Center and , Chair of the UK National Stem Cell Network serving as its Executive Director, he is also a leader of the Cancer Stem Cell Initiative at the Advisory Committee, Director of the EESCN partner at the law firm Holland & Knight, UCD Comprehensive Cancer Center.
    [Show full text]
  • 0001193125-11-216681.Pdf
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A (Rule 14a-101) PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive Proxy Statement x Definitive Additional Materials ¨ Soliciting Material Pursuant to § 240.14a-12 Cryo-Cell International, Inc. (Name of Registrant as Specified in its Charter) (Name of Person(s) Filing Proxy Statement, if Other Than the Registrant) Payment of Filing Fee (Check the appropriate box): x No fee required. ¨ Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11. (1) Title of each class of securities to which transaction applies: (2) Aggregate number of securities to which transaction applies: (3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined): (4) Proposed maximum aggregate value of transaction: (5) Total fee paid: ¨ Fee paid previously with preliminary materials. ¨ Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing. (1) Amount previously paid: (2) Form, Schedule or Registration Statement No.: (3) Filing Party: (4) Date Filed: Presentation to ISS Review of Performance and Shareholder Value Creation Ms.
    [Show full text]
  • Urology Update
    INSIDE Research Update 2 Prostate Cancer Diagnosis Tools 3 News Update 4 Urology BCG Blood Test Proves Beneficial5 Urology Meet Our Faculty 6 Research & Clinical Update MESSAGE FROM THE CHAIR Innovations in Urology Dear Colleagues, As we begin a new year, I am Bioengineered Tissue Constructs for Irreversibly Damaged Penile delighted to update you on Corpora the latest clinical and research Traumatic injuries in civilians and battlefield-related injuries in soldiers often news here at Wake Forest require reconstructive procedures to restore the anatomy and functionality of Baptist Health Urology. From the penis. However, these procedures are often limited by poor availability of a new clinical trial evaluating functionally intact penile tissue. Various penile reconstructive procedures, such bioengineered penile tissue as penile prostheses and autograft implantation, have been attempted. While to continued advancements in cosmetic appearance may be improved, restoration of spontaneous and natural surgical procedures, I am proud erectile function may not be achieved. This is often due to a defect of the of the innovative, pioneering corpora cavernosa, which is critical for erectile function. The concept of a tissue spirit of our faculty. engineering-based therapy has been proposed for reconstructing damaged penile corporal tissue. The clinical work of our faculty is complemented by their An upcoming clinical trial sponsored by the Armed Forces Institute for research endeavors with Regenerative Medicine (AFIRM II) has been designed to evaluate the safety of medical center colleagues, autologous engineered corpora cavernosa + albuginea constructs for treatment Urology Research Laboratory of complex penile deformities. Autologous endothelial and smooth muscle cells, obtained from enrolled subjects’ corpora cavernosa biopsies, will be cultured, and the Wake Forest Institute expanded in vitro and used to seed decellularized corpora cavernosa + albuginea for Regenerative Medicine.
    [Show full text]
  • 2020 Stem Cell Research
    2 | 2021 STEM CELLS PRINT & DIGITAL MEDIA GUIDE REACH THE GLOBAL STEM CELL RESEARCH COMMUNITY About Us. Presenting a collection of premier journals Our media provide in-depth coverageon and digital publications serving the following topics: biomedical researchers in the fast-paced • Cancer Stem Cells area of stem cells and regenerative • Stem Cell Culture • Cell-Based Drug medicine. Included are two leading journals Development, Screening, and devoted to publishing peer-reviewed articles, Toxicology web-based platforms for up-to-the minute • Cell Expansion • Embryonic Stem Cells/ developments, and email outreach for timely Induced Pluripotent Stem (iPS) Cells updates delivered directly to key opinion • Enabling Technologies for Cell-Based Clinical leader’s inboxes. Translation • Fetal and Neonatal Stem Cells 6.022 3,000 Stem Cells 2019 IMPACT AVG. CIRCULATION PRINT ONLINE • Manufacturing FACTOR 100% PAID Advances and Techniques Stem Cells Translational 6.429 18,610 • RegenerativeMedicine Medicine 2019 IMPACT UNIQUE VISITORS PER • Standards, Policies, Protocols, and ONLINE JOUNRAL FACTOR MONTH Regulations for Cell- Based Therapies Stem Cells E-Blasts • Tissue Engineering and 15-20% 12,225 RegenerativeMedicine EMAIL SPONSORSHIP AVERAGE OPEN OPT-IN DISTRIBUTION • Tissue-Specific RATE Progenitor and Stem Cells Regenerative 26.5% 12,225 • Translational Medicine Weekly and Clinical AVERAGE OPEN WEEKLY Research E-NEWSLETTER RATE DISTRIBUTION • Gene and Cell Therapy • Immuno-Therapy • Immuno-Oncology 2021 STEM CELLS PRINT & DIGITAL MEDIA GUIDE | 3 THE PRIMARY PUBLICATION FOR THE FIELD Stem Cells The premier publication venue for the most impactful research in the field, Stem Cells provides prompt, peer-reviewed publication of original research and concise reviews. Read and written by researchers whose expertise encompasses all aspects of stem cell biology, the journal covers everything from basic Editor-in-Chief: Jan A.
    [Show full text]
  • Scientists See Potential in Amniotic Stem Cells - Washingtonpost.Com Pagina 1 Van 2
    Scientists See Potential In Amniotic Stem Cells - washingtonpost.com pagina 1 van 2 Scientists See Potential In Amniotic Stem Cells They Are Highly Versatile And Readily Available By Rick Weiss Washington Post Staff Writer Monday, January 8, 2007; A01 A type of cell that floats freely in the amniotic fluid of pregnant women has been found to have many of the same traits as embryonic stem cells, including an ability to grow into brain, muscle and other tissues that could be used to treat a variety of diseases, scientists reported yesterday. The cells, shed by the developing fetus and easily retrieved during routine prenatal testing, are easier to maintain in laboratory dishes than embryonic stem cells -- the highly versatile cells that come from destroyed human embryos and are at the center of a heated congressional debate that will resume this week. Moreover, because the cells are a genetic match to the developing fetus, tissues grown from them in the laboratory will not be rejected if they are used to treat birth defects in that newborn, researchers said. Alternatively, the cells could be frozen, providing a personalized tissue bank for use later in life. The new cells are adding credence to an emerging consensus among experts that the popular distinction between embryonic and "adult" stem cells -- those isolated from adult bone marrow and other organs -- is artificial. Increasingly, it appears there is a continuum of stem cell types, ranging from the embryonic ones that can morph into virtually any kind of tissue but are difficult to tame, up to adult ones that can turn into a limited number of tissues but are relatively easy to control.
    [Show full text]